Atlas of clinically distinct cell states and ecosystems across human solid tumors
- PMID: 34597583
- PMCID: PMC8526411
- DOI: 10.1016/j.cell.2021.09.014
Atlas of clinically distinct cell states and ecosystems across human solid tumors
Abstract
Determining how cells vary with their local signaling environment and organize into distinct cellular communities is critical for understanding processes as diverse as development, aging, and cancer. Here we introduce EcoTyper, a machine learning framework for large-scale identification and validation of cell states and multicellular communities from bulk, single-cell, and spatially resolved gene expression data. When applied to 12 major cell lineages across 16 types of human carcinoma, EcoTyper identified 69 transcriptionally defined cell states. Most states were specific to neoplastic tissue, ubiquitous across tumor types, and significantly prognostic. By analyzing cell-state co-occurrence patterns, we discovered ten clinically distinct multicellular communities with unexpectedly strong conservation, including three with myeloid and stromal elements linked to adverse survival, one enriched in normal tissue, and two associated with early cancer development. This study elucidates fundamental units of cellular organization in human carcinoma and provides a framework for large-scale profiling of cellular ecosystems in any tissue.
Keywords: CIBERSORTx; EcoTyper; cancer genomics; cell states; cellular communities; ecosystems; ecotypes; expression deconvolution; tumor immunology; tumor microenvironment.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.D. reports research funding from Varian Medical Systems and Illumina; ownership interest in CiberMed and Foresight Diagnostics; patent filings related to cancer biomarkers; and paid consultancy from Roche, AstraZeneca, RefleXion and BioNTech. A.A.A. is a member of the Cell advisory board and reports research support from Bristol Meyers Squibb; ownership interest in CiberMed, FortySeven Inc., and Foresight Diagnostics; patent filings related to cancer biomarkers; and paid consultancy from Genentech, Roche, Chugai, Gilead, and Celgene. A.M.N. reports ownership interest in CiberMed and patent filings related to cancer biomarkers. B.A.L., C.B.S., A.A.A., A.J.G., and A.M.N. have filed patent application PCT/US2020/059196. The remaining authors declare no potential conflicts of interest.
Figures
Comment in
-
Dissecting bulk transcriptomes of diffuse large B cell lymphoma.Cancer Cell. 2021 Oct 11;39(10):1305-1307. doi: 10.1016/j.ccell.2021.09.006. Epub 2021 Sep 30. Cancer Cell. 2021. PMID: 34597590
-
Deciphering the cancer microenvironment from bulk data with EcoTyper.Cell. 2021 Oct 14;184(21):5306-5308. doi: 10.1016/j.cell.2021.09.028. Cell. 2021. PMID: 34653367 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
